Editor’s note: The attached comment letter was submitted to the US Congress on Aug. 18, 2023.
Stricter regulations of the market for non-medical CBD and the products allowed to be sold in it
are required to ensure the public health and public safety of Americans. As scientists, we usually
wait for clear scientific evidence before guiding policy reforms, but we feel it necessary to act
because the industry is moving ahead of the science assuming that new product formulations
derived from the plant are safe because the plant appears to be safe. Policymakers should
consider the regulatory experiences that we have observed from tobacco, vaping products,
alcohol and prescription drug industries when considering the regulation of CBD for nonmedical
use. Those considerations as well as the pharmacological aspects of CBD and our current
knowledge of the endocannabinoid system are reflected in the answers contained herein.
Read the full comment letter here.
Sign up for Schaeffer Center news